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Abstract
Background: Calls for evidence-informed public health policy, with implicit promises of greater program effectiveness, 
have intensified recently. The methods to produce such policies are not self-evident, requiring a conciliation of values 
and norms between policy-makers and evidence producers. In particular, the translation of uncertainty from empirical 
research findings, particularly issues of statistical variability and generalizability, is a persistent challenge because of the 
incremental nature of research and the iterative cycle of advancing knowledge and implementation. This paper aims to 
assess how the concept of uncertainty is considered and acknowledged in World Health Organization (WHO) policy 
recommendations and guidelines. 
Methods: We selected four WHO policy statements published between 2008-2013 regarding maternal and child nutrient 
supplementation, infant feeding, heat action plans, and malaria control to represent topics with a spectrum of available 
evidence bases. Each of these four statements was analyzed using a novel framework to assess the treatment of statistical 
variability and generalizability.
Results: WHO currently provides substantial guidance on addressing statistical variability through GRADE (Grading of 
Recommendations Assessment, Development, and Evaluation) ratings for precision and consistency in their guideline 
documents. Accordingly, our analysis showed that policy-informing questions were addressed by systematic reviews 
and representations of statistical variability (eg, with numeric confidence intervals). In contrast, the presentation of 
contextual or “background” evidence regarding etiology or disease burden showed little consideration for this variability. 
Moreover, generalizability or “indirectness” was uniformly neglected, with little explicit consideration of study settings 
or subgroups. 
Conclusion: In this paper, we found that non-uniform treatment of statistical variability and generalizability factors that 
may contribute to uncertainty regarding recommendations were neglected, including the state of evidence informing 
background questions (prevalence, mechanisms, or burden or distributions of health problems) and little assessment of 
generalizability, alternate interventions, and additional outcomes not captured by systematic review. These other factors 
often form a basis for providing policy recommendations, particularly in the absence of a strong evidence base for 
intervention effects. Consequently, they should also be subject to stringent and systematic evaluation criteria. We suggest 
that more effort is needed to systematically acknowledge (1) when evidence is missing, conflicting, or equivocal, (2) what 
normative considerations were also employed, and (3) how additional evidence may be accrued. 
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Introduction
The role of research findings and evidence-based public 
health policy has become of increasing interest to researchers 
and policy-makers in recent decades.1,2 Much of the evidence-
based policy research has focused on how to improve 
evidence utilization and increase uptake, working on a set of 
assumptions that may neglect consideration of the wider policy 
processes and decision-making contexts.3 Furthermore, there 
is a lack of knowledge about how uncertainty and conflicting 
evidence are considered and treated in these processes.4,5 
This is important because the use of the same evidence for 
policy can differ according to policy objectives in different 
decision-making contexts.6 Consequently, a large gap exists 
in understanding and evaluating how policy-making bodies 
account for uncertainty when using evidence. The World 
Health Organization’s (WHO’s) role as the health authority 
in the United Nations (UN) system presents a particularly 
important institutional context for investigating this issue 
because its functions include establishing standards and 
articulating evidence-based policies for implementation in a 
range of settings and countries around the world. Specifically, 
its formal mandate includes normative powers for the 
production of policy recommendations.7,8 This paper aims 
to assess how the concept of uncertainty is considered and 
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acknowledged in WHO policy statements. 
WHO as a Context for Assessing the Translation of Empirical 
Evidence
As the traditionally recognized international institution 
that sets norms for public health, there is an expectation 
for WHO to produce policy recommendations that are 
based on scientific evidence.9 Oxman et al found a general 
lack of systematic and transparent methods for developing 
evidence-informed WHO guidelines, and that processes for 
making recommendations relied on content experts rather 
than methodologists or guideline users.10 Knowledge on the 
barriers and facilitators of evidence use by decision-makers 
for health policy appears to support the two communities 
hypothesis that researchers and policy-makers are two 
separate groups with distinctly different cultures.11-13 However, 
in the decision-making context of WHO as the international 
agency responsible for health, the division between these 
groups is not clear. Commentators have debated about the 
potential consequences of an overlap in WHO’s technical 
and political functions in executing its mandate, and the 
need for transparent processes to ensure scientific credibility 
and legitimacy with an increasingly crowded landscape of 
actors involved in global health governance.14-16 The use of 
evidence by WHO has been previously criticized on several 
fronts.3,10 For instance, the diversity of evidence sources 
used and the transparency of the development process for 
guidelines has been questioned.17 Since the publication of 
the WHO’s Handbook for Guideline Development in 2014, 
WHO recommendations have been further criticized to be 
inconsistent with GRADE (Grading of Recommendations 
Assessment, Development, and Evaluation) guidance.18 
GRADE is a WHO working group that has developed an 
approach to grading quality (or certainty) of evidence and 
strength of recommendations. In general, these critiques 
focus on the quality and nature of evidence for (or against) 
the effects of specific interventions. However, as recognized 
by the 2014 Guidelines, additional sources of evidence are 
drawn upon to motivate policy recommendations, including 
“background” evidence. Moreover, the usage of any forms 
of evidence evaluation (eg, systematic review, GRADE 
rating), etc nonetheless remain distinct from the final policy 
recommendations. We propose to evaluate the totality of 
scientific evidence usage across the policy-making process, 
paying particular attention to how uncertainty in the scientific 
evidence base is represented throughout. 
Getting Evidence Into Policy
For evidence to inform policy recommendations, research 
findings must still be “translated” for decision-makers 
regarding their applicability for a given setting or population. 
Knowledge translation is one strategy to improve the use 
of evidence in policy.3 The Canadian Institutes of Health 
Research (CIHR) define knowledge translation as a “dynamic 
and iterative process that includes synthesis, dissemination, 
exchange and ethically-sound application of knowledge” 
(http://www.cihr-irsc.gc.ca/e/29418.html). Knowledge translation 
research is a domain of scientific inquiry by itself,19-22 
producing tools and methods to support implementation of 
public health knowledge translation activities.23,24 However, 
little attention has been paid to the empirical realities of how 
evidence “survives,” or may be reshaped, by this translation 
process. There is a nascent body of knowledge about public 
health policy-making that demonstrates how evidence is 
but one kind of argument for influencing policy change in a 
complex network of policy actors25 and how different kinds 
of research-informed ideas are used by policy-makers to 
interact within the policy process.26 These studies underline 
the importance of the realities of policy-makers, and policy 
theory can inform strategies for evidence-based public health 
policymaking which better account for their decision-making 
processes, including how they deal with uncertainty.27 Given 
the above, it is problematic that few studies on the use of 
evidence in policy clearly define the terms evidence, policy 
or policymaker.13
What Is Scientific Evidence?
In its broadest sense, evidence denotes any “body of facts or 
information indicating whether a belief or proposition is true 
or valid.”28 Following on from evidence-based medicine,29 
evidence for public health policy not only refers to general 
bodies of information, such as demographic or survey data, 
but also specific products of empirical social and biomedical 
research, here termed “scientific evidence,” such as results of 
disease etiology or intervention studies.2 It is important to 
note that there is an ongoing scholarly debate on the definition 
Implications for policy makers
• Taking World Health Organization (WHO) policy statements as a well-studied context for evaluating the translation of scientific evidence, we 
suggest that more effort is needed to acknowledge when evidence is missing, conflicting, or equivocal beyond that addressed by systematic 
review of intervention effects, including in background knowledge. Consequently, it should be made explicit what normative considerations 
were employed in lieu of such knowledge, and where relevant knowledge gaps exist.
• We propose some recommendations for the consideration of uncertainty in future WHO policy recommendations documents. These 
recommendations may help provide to policy-makers a more accurate picture of the state of evidence.   
Implications for the public
The translation of uncertainty from empirical research findings into policy recommendations is a persistent challenge because of the incremental 
nature of research and the iterative cycle of advancing knowledge and implementation. In this paper, we highlight that even when quality of evidence 
is systematically evaluated with respect to effects of specific interventions, uncertainty with respect to the state of supporting evidence, including 
issues of generalizability, may be overlooked. This paper reinforces the notion that evidence used to motivate policy is multifaceted and systematic 
evaluation is quite challenging. 
Key Messages 
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of evidence for public health policy.1,30,31 
Brownson et al32 propose three categories of scientific evidence 
relevant for informing public health policy: first, evidence for 
causal associations between a disease state and a potential risk 
factor that can be addressed through a public health policy 
(eg, air pollution and lung cancer33); second, evidence of 
potential impact or effectiveness of a specific intervention (eg, 
reduction of fuel sulfur content on mortality34); third, and least 
commonly, evidence for “external validity” – what features 
of and contexts for implementing interventions contributed 
to the efficiency of the policy. We will refer to these types as 
Causality, Effectiveness, and External Validity, respectively. 
Empirical strategies for producing this evidence are diverse 
and lead to a variety of potential products that may be used to 
validate truth claims in policy. Among these products, norms 
are used for classifying and ranking quality, or “strength of 
evidence” that are widely shared by empirical researchers and 
embodied by preeminent research institutions. 
For example, researchers highly value systematic reviews, 
exhaustive summaries and syntheses of empirical studies 
which address a single question or family of questions.35 
Many guidelines exist to help those who conduct systematic 
reviews in the service of policy-making. Institutions such as 
the Cochrane or Campbell Collaborations36 provide various 
tools for conducting systematic reviews and integrating 
their results in translation processes for policy, especially for 
evidence of first or second type. In these guidelines, sources 
of information are generally ranked similarly, with scientific 
studies subjected to peer-review holding the greatest value, 
with various criteria about study design and analytic methods 
creating further subdivisions.37 For the purposes of “strength 
of evidence,” other sources of information are generally 
considered to be of lesser quality. This includes grey literature 
or studies not subjected to journal-based peer-review, expert 
consultation and community-based knowledge.37 
What Is Uncertainty?
Uncertainty in the setting of empirical evidence production 
and translation is understood to arise from various domains. 
For example, biases in study design and measurement are 
important source of uncertainty in evidence production. 
When translating and interpreting empirical evidence, these 
uncertainties may be represented by specific modalities. 
Based on the three categories of scientific evidence defined 
above (Causality, Effectiveness, and External Validity), we 
have chosen to focus on two modalities: statistical variability 
and generalizability. Statistical variability can be defined as 
“the estimated range of values which is likely to include an 
unknown population parameter, the estimated range being 
calculated from a given set of sample data.”38 It is a way for 
scientists to systematically demonstrate that they do not know 
a quantity exactly, for example the proportion of individuals 
under the age of 45, and the extent to which they are unsure 
of their estimate. This may be due to several reasons, such as 
not being able to measure everyone in a target population, 
and can also be applied to estimates of effect, for example 
the proportion of individuals that would be cured by a 
given treatment. In practice, the concept is linked directly 
to confidence intervals circling a potential ‘true’ parameter. 
For example, a 95% confidence interval means that if the 
same population is sampled on many occasions and interval 
estimates are made at each time, the resulting intervals would 
circle the ‘true’ population parameter in approximately 95% of 
the cases. Accordingly, very uncertain estimates, as indicated 
by wide ranges for confidence intervals, can qualitatively 
provide an indication that the scientific evidence supporting a 
certain truth claim (for example, that there is a high proportion 
of individuals under 45, or that an intervention is effective in 
curing disease) is weak. Consequently, statistical variability 
is an important attribute for the first two types of scientific 
evidence described above – Causality and Effectiveness. In 
contrast, “generalizability” is related to the extent to which 
the results of one study can be applied to other contexts 
and populations and thus directly corresponds to the third 
type of scientific evidence – External Validity. This notion 
of external validity has been largely discussed in academic 
literature, but remains quite a complex topic that defies 
simple quantification.39 Faithfully representing uncertainty 
that arises from empirical research are fundamental to the 
process of justifying public health policy recommendations 
that both (i) embrace the variability inherent in empirical 
evidence-making and (ii) consider the issues of applying 
conclusions from one population/place to another. We note 
again, that while evaluations of uncertainty (eg, bias) of 
the body of scientific evidence and how it should be used, 
which is accomplished by many expert bodies including the 
Cochrane collaboration, the in vivo usage of these evaluations 
and the source findings themselves in policy statements is a 
distinct process. To our knowledge, there have been no other 
evaluations of how these collection of tools ensure, or not, 
faithful translation of evidence (or evidence synthesis) to 
actual policy recommendations.
In order to address how these two uncertainty components 
are translated and incorporated in policy recommendations, 
we chose to focus on four case studies of WHO policy 
statements, in which the process of evidence-based policy-
making has been given significant attention, and where 
uncertainty, particularly in generalizing recommendations is 
an essential consideration. 
Methods
We first reviewed WHO’s standards and rules regarding 
“evidence-informed” guideline creation to capture the norms 
and values the organization establishes for this practice. To 
contextualize our specific policy analyses, we described key 
features of the WHO guideline development process and 
the values that motivate them found in the WHO Handbook 
for Guideline Development.37 These aspects are presented in 
Appendix 1. 
Analytical Framework
To our knowledge, this is the first study to-date to investigate 
the translation elements of uncertainty into public health 
policy recommendations. Consequently, we propose a novel, 
practical, and adaptable framework as a first attempt to 
formalize the evaluation and rating of uncertainty translation 
(Table). The framework consists of four domains by which 
we evaluate the translation of each of the two components 
of uncertainty discussed above (ie, statistical variability and 
generalizability). The domains are as follows: 
Benmarhnia et al
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A. Use of uncertainty information from empirical studies, 
B. Critique or discussion of such information, 
C. Translation into policy recommendation, 
D. Discussion of new uncertainty introduced by the 
recommendation.
For each item, we propose several criteria or subcategories 
as shown in Table. For Statistical Variability, we consider 
whether the statement provides representations of statistical 
uncertainty via presentation of confidence intervals (Domain 
A) or discussion of the precision and other statistical 
limitations of cited evidence (Domain B). For Generalizability, 
we consider how closely recommendations aligned with the 
interventions evaluated in reviews (C) and whether provide 
recommendations acknowledged issues with generalizability. 
These subcategories were organized into a worksheet 
consisting of both quantitative and qualitative elements 
(Table). This framework was intended to elicit element we 
felt to be important to the translation of empirical findings 
and does not aim to provide a comprehensive list of criteria 
under all four of the domains that all WHO guidelines or 
recommendations should be meeting.
Two reviewers (TB and JYH) completed this worksheet for 
a common documentation in order to test its content. We 
chose “Closing the Gap in a Generation,” a report of the WHO 
Commission on Social Determinants of Health,40 for the pilot 
since it was a policy document where the fields of expertise of 
both reviewers overlapped. Based on this pilot, modifications 
to the worksheet including eliminating elements for which 
there was substantial overlap in content and altering 
commonly described elements, such as confidence interval, 
from qualitative descriptions to counts. We did not include 
any ranking of importance for the domains of the analytic 
framework. 
Case Selection and Materials
Each reviewer then selected two WHO guidelines from 
those produced between 2008 and 2013 based on their 
expertise in two fields, namely: Maternal and Child Health 
and Environmental Health. The four cases of WHO policy 
recommendations/statements selected were: maternal 
vitamin D supplementation (JYH); infant feeding (JYH); 
the heat health action plan (TB); and Malaria Policy 
Advisory Committee (MPAC) recommendations (TB). 
While a convenience sample not meant to be representative 
or systematic, these cases included policy statements from 
a range of settings in which the evidence base was limited 
(vitamin D) or extensive (Malaria) or where existing policy 
was numerous (infant feeding) or rare (Heat). 
Data Analysis 
Each reviewer first read the two WHO policy statements 
corresponding to their field of expertise and described each 
Table. Analytical Framework for Evaluating Translation of Uncertainty in Empirical Studies to Policy Recommendations
Domain Criteria Action
Statistical Variability
Domain A - Use 
of uncertainty 
information from 
empirical work
Reporting values (number of attributable cases, years of life lost, $, % etc) Count # qualitative (non-numeric) citations 
Count # point estimates/graphs without error bars
Count # point estimates/graphs with error bars
Reporting associations/risk Count # qualitative (non-numeric) citations 
Count # point estimates/graphs without error bars
Count # point estimates/graphs with error bars
Reporting intervention/program evaluation results Count # qualitative (non-numeric) citations 
Count # point estimates/graphs without error bars
Count # point estimates/graphs with error bars
Domain B - Critique or 
discussion of empirical 
work used
Presence of a statement of how they use the original data Select (Yes/No) and comment(s)
Acknowledgments of the limits by using original data Select (Yes/No) and comment(s)
Discussion about timing of evidence Select (Yes/No) and comment(s)
Independent assessment of references Select (Yes/No) and comment(s)
Reporting uncited facts One comment for each instance
Use/misuse of causal language One comment for each instance
Generalizability
Domain C - 
Translation into policy 
recommendation
Inclusion of a statement or a description about how evidence was used to 
make WHO recommendations
Select (Yes/No) and comment(s)
Statement includes qualifications found in citation Select (Yes/No) and one comment for each instance
Statement matches finding from citation Select (Yes/No) and one comment for each instance
Each recommendation corresponds to findings from one or more citations 
or systematic reviews
Select (Yes/No) and one comment for each instance
Domain D - Discussion 
of new uncertainty 
introduced by the 
recommendations
Ask for further work in new areas Propose additional research areas: Comment(s)
Discuss criteria for generalizing: Comment(s)
Introduce limitations of recommendations made Other health/intervention concerns: Comment(s)
New context: Comment(s)
Temporal considerations: Comment(s) 
Call for monitoring and evaluation about the recommendations/updates Select (Yes/No) and comment(s)
Abbreviation: WHO, World Health Organization.
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by summarizing the process of its production, the declared 
aims of the policy, and its general structure. Then, each 
reviewer completed a worksheet for each statement. Next, 
the reviewers summarized general themes and results from 
their respective worksheets. Finally, the reviewers met to 
discuss common and emergent themes from the reviews. 
While each reviewer read the notes and worksheets of the 
other and discussed interpretations that were unclear, no 
attempts to cross-verify or replicate the results were made. 
Again, these reviews were intended to elicit themes regarding 
the translation of empirical findings and not a definitive 
evaluation. The reviews were conducted independently 
between the 2 reviewers. Documents were analyzed using 
thematic analysis41 by combining the four domains and 
subcategories with additional emergent themes in a deductive 
way. Each section of the different documents was thus 
analyzed using this process. Finally, the data was synthesized 
using identified themes. 
Results
We included four cases of WHO guidelines encompassing 
different public health policy areas. We found an important 
heterogeneity across these different guidelines according to 
the guideline format and structure, the motivations of the 
document and the overall process. It is also interesting to note 
that most recently published documents are more transparent 
in terms of the policy-making process and sources of evidence 
that are mobilized. This may be due to the publication of 
different WHO statements in the last years including the 
WHO Handbook for Guideline Development (see details in 
Appendix 1) in 2014. 
Vitamin D Supplementation in Pregnant Women42
This guideline was initiated due to a request from Member 
States for guidance on “the effects and safety of vitamin 
D supplementation in pregnant women as a public health 
strategy” to achieve Millennium Development Goals (pp 
1). This interest was informed by beliefs that pregnant 
women were widely deficient in vitamin D and findings of 
associations between deficiency and a number of adverse 
pregnancy and birth related outcomes (Framework Domain 
B). The guideline specified that Handbook procedures were 
followed and that evidence was evaluated by a designated 
existing Guideline Development Group (GDG), the Nutrition 
Guidance Advisory Group (Framework Domain B) (pp 1). In 
summarizing the evidence, the GDG identified one Cochrane 
systematic review on vitamin D supplementation on maternal 
and neonatal outcomes and made a strong recommendation 
against supplementation to prevent maternal pre-eclampsia 
and a conditional recommendation against routine 
supplementation (Framework Domain D).
Generally, representation of empirical work was qualitative 
(reporting trends and associations without numbers) when 
addressing background questions on mechanisms and more 
precision with numerical estimates and confidence intervals 
when addressing key (foreground) questions (Framework 
Domain A). The citation of empirical evidence was fairly evenly 
split between the two (Framework Domain B). The Cochrane 
review used to answer key questions was conducted by a WHO 
epidemiologist of the GDG (Framework Domain C). The 
summary of evidence, including GRADE criteria, were drawn 
directly from review and perhaps as a consequence, no further 
consideration of the strength of the review or any new issues of 
uncertainty raised was apparent (Framework Domain D). For 
example, the risk of side-effects from supplementation had a 
wide confidence interval (risk ratio = 0.17 [95% CI: 0.01-4.06]) 
and was cited as evidence for no effect, despite substantial 
uncertainty regarding precision (Framework Domain A) 
(pp 4). Additionally, questions about the generalizability of 
the limited randomized controlled trials (RCTs) conducted 
mainly in France and the United Kingdom or the potential 
benefits for subgroups, such as vitamin D deficiency, were 
not clearly addressed (Framework Domain D). Nonetheless, 
statements regarding key questions were generally measured, 
confidence intervals were presented to indicate uncertainty, 
a current lack of high quality studies was acknowledged, and 
deliberate plans for re-review of evidence in 2016 was stated 
(Framework Domain D). Moreover, the guidelines were clear 
to disclose what other factors were considered by the GDG 
to make recommendations (see Appendix 1). On the other 
hand, the evidence used to address background questions 
including questions of potential mechanisms of action, as 
alluded to above, was less careful in their attempted use of 
empirical evidence (Framework Domain D). This included 
the use of uncited facts about biological effects of vitamin D 
and attribution of casual mechanisms for vitamin D based 
on theory or single, observational studies (pp 3) (Framework 
Domain B). Furthermore, a justification of the works cited 
for background, as the Handbook suggests, or any contrary 
empirical findings omitted was not apparent. 
Nutritional Interventions Targeted at Young Infants (0–5 
months)43
These guidelines were adapted from existing guidelines 
and incorporated into consolidated guidance on “Essential 
Nutrition Actions: Improving Maternal, Newborn, Infant 
and Young Child Health and Nutrition.” The guidelines for 
young infant (0–5 months) feeding evaluated for this paper 
consisted of a set of four policy recommendations: early 
initiation of breastfeeding at birth, exclusive breastfeeding 
for 6 months; mother or donor milk feeding for low birth 
weight infants; and exclusive breastfeeding by HIV-infected 
mothers. While there was a stated commitment that most 
recommendations were updated to comply with the evidence-
informed standards in the 2012 Handbook (Preface), it is not 
clear from the Handbook or the guideline statements how 
such updating would occur, for example whether new GDGs 
would be convened to re-asses the evidence (Framework 
Domain C). Moreover, several of the policy statements were 
developed in conjunction with other groups such as the 
United Nations International Children’s Fund (UNICEF), 
further complicating any adherence to Handbook standards 
(Framework Domain B).
Overall, statistical variability and confidence intervals 
were infrequently cited or considered in the presentation 
of empirical evidence. Similar to the vitamin D guidelines, 
attempted to use evidence to address background questions 
as to the importance and burden of child malnutrition 
through breastfeeding were hampered by uncited facts, and 
associations cited as causes (pp 2-4) (Framework Domain A). 
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Most notably, the suggestion in the background that there was 
causal evidence for early breastfeeding in preventing infection-
related neonatal mortality cited a single observational 
study suggesting association (pp 11) (Framework Domain 
B). Unlike the vitamin D supplementation guideline, 
however, the lack of consideration for uncertainty was also 
apparent in the addressing of key questions related directly 
to the recommended interventions (Framework Domain 
C). For example, a Cochrane review of community-based 
interventions to improve maternal and neonatal outcomes 
was cited as providing a “statistically significant impact on the 
intuition of breastfeeding within 1 hour of birth” in reference 
to an average relative risk of 1.94, without any confidence 
intervals. Additionally, a large confidence interval (7% to 
70%) for the effects of early breastfeeding interventions on 
increasing sustained breastfeeding was considered evidence 
for being “effective” (pp 14). Relatedly, the generalizability or 
“indirectness” of summarized evidence was poorly considered, 
leaving questions of the relevance of systematic reviews to 
answering key questions as well as the identity of the key 
questions themselves (PICO-format questions, eg, Population, 
Intervention, Comparator Interventions, Outcomes, were 
not apparent) (Framework Domain C). Other evidence cited 
as relevant systematic reviews include references that were 
not per se, for example summary of findings from expert 
consultation (pp 13, Table I-2) (Framework Domain B). Like 
the supplementation policy, the new uncertainty issues raised 
by the systematic review were not appropriately considered. 
Most importantly, while a prominent 2001 systematic review 
on the impact of exclusive breastfeeding was considered along 
with a 2009 update, the most recent update in 2012, was not 
(pp 12) (Framework Domain B). Consequently, subtle issues 
such as the need to manage infants individually based on 
growth, or the potential harms of exclusive breastfeeding to 
iron-deficient infants was overlooked.44 Moreover, systematic 
evidence for certain recommended actions, such as maternal 
support in the workplace was absent, and other means of 
justification were unclear (pp 14) (Framework Domain C). 
On the other hand, the lack of evidence on policies for HIV-
infected mothers was clearly and transparently stated and the 
alternative justifications by principles and context were clearly 
outlined (pp 17-18) (Framework Domain B). Additionally, 
the guideline was able to use the identification of sub-optimal 
study types (non-randomized and cross-sectional) to justify 
quality of evidence for an equivocal effect of early breastfeeding 
promotion practices. Finally, the availability of evidence to 
address the Member State implementation question and 
special considerations for subpopulations (in the two policies 
not related to sub-populations) were not considered despite a 
strong recommendation for implementation in all countries 
(Framework Domain D). 
The Heat Health Action Plan45
This document was motivated by both the extraordinary heat 
wave that occurred in 2003 in Europe that caused serious 
health and social issues, and the contemporaneous findings 
by the Intergovernmental Panel on Climate Change (IPCC) 
projecting the effects of climate change on human health.46 
The document’s foreword states that “Recommendations in 
this publication are based on results of the two-year project on 
improving public health responses to extreme weather/heat-
waves (EuroHEAT).” The stated objective of this report was 
to “describe the general principles and core elements of national 
or regional heat–health action plans, gives options and models 
for interventions and practical examples and tools from various 
European countries.” 
The authors of the guidelines did not explicitly present the 
methodology on which they based their recommendations, 
but specified that the content was based on research results, 
experience, and lessons learned (Framework Domain B). 
They also highlighted that the policy process was mostly 
based on the EuroHEAT project, which was conducted by 
an expert panel. This document was also complementary to 
a technical document “Preparedness and response to heat-
waves in Europe, from evidence to action,” which contained 
their review of the scientific literature. The latter was therefore 
included in our assessment. 
Empirical results (both for associations between heat and 
health and intervention evaluations) were mostly reported 
qualitatively (Framework Domain A). Yet in some sections, 
results and figures, estimates are largely presented with 
confidence intervals (Framework Domain A). For example, the 
section about short-term relationships between temperatures 
and health outcomes highlighted statistical variability, while 
the section about vulnerable populations did not. Regarding 
vulnerable populations, it should be further noted that the 
guideline did not consider some empirical evidence showing 
opposite results. For example, the statement that “infants 
and children are sensitive to the effects of high temperatures” 
contrast with other epidemiologic findings including a recent 
systematic review.47
Indeed, similar to the previous policies, the empirical evidence 
used to motivate background questions, including the etiology 
of vulnerability to heat, was generally weak (Framework 
Domain B): A discussion about the determination of the 
sufficient level of evidence to characterize vulnerability to heat 
was absent and a single narrative review48 was used to describe 
the phenomenon. Furthermore, neither statistical variability 
nor generalizability were duly considered when a single study 
was used to justify the statement (Framework Domain C): 
“In general, the impact of hot weather on hospital admissions 
appears to be lower than the impact on mortality.” Moreover, 
the authors did not include an explicit section acknowledging 
the limits of available data (Framework Domain B). There is 
only this brief disclaimer in the foreword: “These suggestions 
for countries need to be scrutinized for their respective 
feasibility and applicability on a national or regional basis 
and may need to be adapted accordingly.” This aspect is 
not discussed further in the document, nor any motivating 
evidence provided for guidance.
However, the authors dedicated a large part of the document 
asking for further study (Framework Domain D), especially 
policy evaluation studies and providing further etiologic 
evidence about heat effects and vulnerable subgroups. They 
also specifically acknowledged that their recommendations 
only reflect the current, limited quantity of evidence 
(Framework Domain D). Additionally, authors contributed 
a dedicated section, including methods and indicators, 
to support monitoring and evaluation following policy 
implementation (Framework Domain D). 
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Malaria Policy Advisory Committee (2014)
We assessed a set of related recommendations made by 
the MPAC. This committee was created in 2011 to provide 
independent strategic advice to WHO on developing policy 
recommendations on malaria control and elimination. They 
have a dedicated web page (http://www.who.int/malaria/
mpac/en/) which provides a detailed, transparent account of 
their policy recommendations processes (Framework Domain 
B). For example, they publish all their expert meeting reports. 
This committee is supported by evidence review groups and 
technical expert groups. The former assesses the evidence 
(both Causality and Effectiveness-types) in the existing 
scientific literature following the WHO guidelines while the 
other make the policy recommendations (see description 
above). Recommendations are made for very specific 
objectives in malaria control (eg, “Intermittent Preventive 
Treatment [IPT] in Pregnancy,” or “Safety and Efficacy of 
Gametocytocidal Doses of Primaquine for Plasmodium 
Falciparum Malaria”) (Framework Domain C). 
In evidence review documents, statistical variability is well 
reported including point estimates and confidence intervals 
from empirical studies, and discussions thereof (Framework 
Domain A and B). Critically however, limitations of empirical 
evidence are generally discussed only in the context of 
studies that present a challenge to their conclusions or 
recommendations (Framework Domain B). For example, in 
the evidence review document on Malaria Diagnosis in Low 
Transmission Settings, the critique of observational studies is 
mainly present for negative results about the efficiency of a 
program. 
On their website (see above), they state how they classify the 
original data they use (Framework Domain B). There, they 
largely discuss the limited generalizability of evidence from 
the original data and their recommendations (Framework 
Domain D). However, a section devoted to discussing the 
limitations of their own recommendations is uncommon. 
Additionally, calls for monitoring and evaluation of 
recommended programs and updates to the evidence are 
frequently missing (Framework Domain D). 
Discussion
Summary and Discussion of Findings
First, we must acknowledge that the systematic collection 
and review of empirical evidence, while the primary 
fodder for translation evaluated herein, in fact, is only one 
of many inputs into the WHO policy recommendations 
development process. Moreover, the practice of adapting 
existing guidelines, including those developed in conjunction 
with external partners to adhere to newer standards for 
evidence-informed policy is not clear or straightforward. 
Nonetheless, we found the quality of translating uncertainty 
due to statistical variability and generalizability to be quite 
predictable with respect to the guidance provided by the 
Handbook. Specifically, uncertainty was poorly considered 
in the presentation of evidence used to address background 
questions of prevalence, mechanisms, and burden or 
distributions of health problems. Despite guidance to justify 
any evidence cited,37 the use was non-systematic and in many 
cases, no numerical or confidence interval information was 
provided, no conflicting evidence presented, and strength 
of evidence was generally overstated (associations as causal 
effects). In addition, such poor consideration of uncertainty 
in the presentation of evidence in WHO guidelines can have 
important implications. An important implication could 
be for example that it may not adequately acknowledge the 
importance of context nor encourage the implementation 
of local experiments for which implementation and impact 
evaluation would be conducted. Indeed, if the need for 
translating and adapting interventions for different contexts is 
not appropriately acknowledged in a given WHO guideline, it 
may lead to the direct implementation of an intervention. Yet, 
by doing so, less evidence will be produced across different 
contexts that may useful to produce knowledge about 
generalizability resulting in an unproductive feedback loop.
In contrast, the systematic review of evidence, strongly 
laid out in the Handbook and supported by numerous 
known tools and frameworks (PICO, GRADE, Cochrane) 
was more deliberate in the representation of uncertainty 
including frequent use of confidence intervals (see details in 
Appendix 1). However, perhaps due to the limited guidance 
in the Handbook, little consideration was often given to 
the generalizability of evidence, alternative interventions, 
qualifications of systematic review findings, and new issues 
of uncertainty derived from the reviews. One potential reason 
is the close working relationships between the GDGs and the 
reviewers whether they be Cochrane employees, WHO staff, 
or GDG members themselves. On the other hand, certain 
subtleties indicated by reviewers, such as potential adverse 
effects amongst subgroups, were often lost in guideline 
development in favor of simple recommendations statements. 
Most troublingly, some recommendations were made without 
reference to either evidence or any other relevant factors 
noted by the WHO Handbook (see Table A1 in Appendix 
1), thus their appropriateness was difficult to judge. Finally, 
factors such as publication bias were never considered.
We found the use of evidence, even reviews, to be particularly 
opaque and deterministic, even when issues of variability 
are reasonably translated, highlighting the role of evidence 
as a rhetorical rather than an instrumental informant of 
policy. Even when evidence was systematically reviewed (eg, 
MPAC), recommendations often avoided subtle issues raised 
and may even be unrelated to the evidence produced. These 
discrepancies were clearest when (a) commitments to other 
standards or recommendations were acknowledged and 
(b) when guideline making deviated from the established 
standards. 
We believe greater care should be taken in the translation 
of uncertainty, particularly since it is motivation for policy-
making in the first place. Moreover, we emphasize that any 
participants in WHO policy-making processes should make 
clear when other factors, such as previous knowledge and 
commitments to action circumscribe or influence the current 
use of knowledge. In the case of vitamin D supplementation 
for example, strong recommendations were made on the 
basis of limited evidence, presumably based on principles of 
minimal harms. However, such justifications should be more 
openly discussed. Moreover, newer fields of empirical data 
analysis have suggested avenues for dealing with statistical 
uncertainty including estimating bounds for causal effects49 
or to implement more complex simulation based approaches 
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such as agent-based modelling.50 While the application of such 
practices to policy-making in vivo has yet to be explored, at the 
very least, advisory groups would be served by remembering 
to include confidence bounds and considerations for other 
sources of uncertainty. Moreover, while a variety of evidence 
is indeed needed to motivate new policies (ie, in background 
sections of these documents), better care should be taken 
with regards to the interpretation of observational evidence 
including the consideration of contrary findings or alternative 
interpretations. 
We also found some practices to be exemplary, including 
the MPAC, and further policy recommendations working 
groups should replicate their efforts at transparency. Yet, one 
may argue that in many public health fields, the presence of 
strong empirical evidence such as experimental studies is 
not as readily available as they were for malaria control. It 
is often the case that policy is recommended in the absence 
of strong scientific evidence, and that a recognized need 
from constituents can be a strong and legitimate sufficient 
motivation. In these cases, it is especially important to be 
clear when recommendations do not strictly come from 
strong scientific evidence. Another good example of this was 
the feeding recommendation for HIV-infected mothers. 
Limitations 
We note again that this study aimed to apply a novel 
framework to elicit challenges in the translation of uncertainty 
from empirical studies to policy recommendation. As such, 
it was not intended, at this stage, to be as a definitive tool 
for evaluating WHO or other policy statements. Several 
limitations must be addressed in order for this tool to become 
more applicable. First, the domains selected for evaluating 
evidence transition must continue to be refined for both 
content and reproducibility. Notably, Domain A which is 
highly quantitative is likely to be highly reproducible while 
Domain C, which is qualitative and unstructured, unlikely to 
be so. Additionally, if the framework is itself to be turned in to 
a generalizable instrument its replicability needs to be tested 
by independent reviewers (on the same policy statement) 
and in other policy contexts. Nonetheless, we found this 
framework to have good-face validity in capturing many of 
the concerns we had in the use of evidence in the reviewed 
statements. 
Recommendations 
Based on our admittedly preliminary analysis, the notion of 
uncertainty does not appear to be fully and homogeneously 
addressed in the four cases of WHO policy recommendations 
we reviewed. Acknowledging that each public health topic has 
its own challenges towards the two uncertainty components 
we addressed in this paper and WHO translation through the 
policy-making process, we fully recognize the limitations of 
the framework to completely solve such challenges. However, 
we encourage policy actors with a strong commitment 
to evidence-based decision making to consider some of 
the issues we have explored here, with a particular focus 
on transparency and systematically including sections of 
guidelines relating to uncertainty. To that end, we propose 
the following list of sections to be included in WHO policy 
recommendations and guidelines: 
• Description of how the empirical scientific evidence was 
assembled and assessed (Causality and Effectiveness).
• Description of how a hierarchy in the empirical data was 
considered and what approach was used (Framework 
Domains A, B, C).
• Discussion of the limitations that are presented in the 
original data. These discussions can include timing of 
evidence, validity limitations described in the original 
material, limitations about external validity (Framework 
Domain B).
• Discussion of the new uncertainty introduced by the 
policy recommendations. This section can include 
discussion about generalizability, changing over time, 
and local policy contexts (Framework Domain D). 
• Recommendations and explicit guidelines about 
monitoring and evaluation of the recommendations 
introduced (Framework Domain D).
Additionally, we noted that the role of evidence in informing 
generalizability was largely avoided in the WHO policy 
guidelines we reviewed. While this may be a function of 
WHO’s position as needing to inform broad recommendations 
for diverse member states, it is our opinion that some 
guidance should be provided to direct how evidence may 
be used to inform context-specific recommendations and 
may be needed even in overarching recommendations. One 
idea may be to employ novel innovations in causal modeling 
such as generating effect bounds or agent based modelling 
to operationalize member-state specific knowledge about 
compliance or local average effects. The use of qualitative 
methods to better understand barriers and facilitators for 
implementing WHO policy recommendations and guidelines 
in specific contexts are complementary to the methods 
recommended presently. Approaches to guide where 
generalizability is or is not informed by scientific evidence 
may be helpful to better understand potential policy efficacy 
within specific contexts.
Conclusion
Policy recommendations made by WHO, the foremost public 
health organization in the world, carry substantial weight with 
a variety of decision-makers and practitioners. Our assessment 
of four WHO policy statements and recommendations found 
that the presentation of the evidence in these cases lacked a 
clear and systematic consideration of uncertainty, a problem 
that is exacerbated by absence of explicit references to the 
evidence selected and the recommendations made in some 
instances and the inadequate discussion of new uncertainties 
generated by such policy recommendation. These findings 
underscore that even in the institutional context of an 
intergovernmental organization such as WHO, which has 
a substantial commitment to evidence-based health policy, 
the interpretation and consideration of uncertainty is an 
important problem for the instrumental uses of scientific 
evidence in policy-making. It is unlikely that WHO policy 
recommendations in the areas we selected are outliers in their 
treatment of evidence, and we may expect similar results in 
WHO recommendations on other issues, in particular those 
with a dearth of experimental studies. This is why we argue 
that more work is needed to consider how best to translate 
uncertainty from empirical studies to policy recommendations, 
Benmarhnia et al
International Journal of Health Policy and Management, 2017, 6(11), 649–660 657
with particular attention given to WHO recommendations 
which are founded more on normative values or principles 
rather than empirical bases. Our recommended list of 
additional sections for inclusion in WHO policy statements, 
recommendations, or guidelines all relate to increasing the 
transparency of how evidence is used in these documents. 
Hawkins and Parkhurst51 argue that transparency of decisions 
about identification and evaluation of appropriate evidence 
and its use to inform policy is a significant criterion for the 
good governance of evidence. We suggest that the framework 
used in this paper for the purpose of analyzing how the 
concept of uncertainty is interpreted and acknowledged in 
WHO policy recommendations and guidelines may also be, 
with more testing, a useful contribution to future revisions to 
the WHO Handbook for Guideline Development. 
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Appendix 1. A Summary of the World Health Organization’s 
Guideline Development Processes and Practices
From the outset in its introduction, the WHO Handbook for 
Guideline Development situates the reasons for the organization’s 
practices for developing guidelines within a context of uncertainty 
that surrounds the decision-making processes for public health 
policies.
“WHO develops guidelines whenever Member States, WHO 
country offices, external experts or other stakeholders ask for 
guidance on a clinical or public health problem or policy area. 
This generally happens when they are uncertain about what 
to do or how to choose among a range of potential policies or 
interventions. Uncertainty can be triggered by a new public 
health problem or emergency; the uncovering of new evidence; 
an absence of good-quality evidence (or of any evidence at all); 
or a change in resource availability or access to services.” “1.2. 
Why does WHO develop guidelines?” WHO Handbook for 
Guideline Development (2nd ed.); pp 1.
WHO processes for developing evidence-based guidelines 
and policy statements are ideal case studies on uncertainty for 
several reasons. First, as arguably the most widely recognized 
and influential international body making evidence-informed 
health policy guidance, WHO has a commitment to a transparent 
and systematic use of evidence as outlined in their Handbook for 
Guideline Development and approved by the Guideline Review 
Committee (https://www.who.int/kms/guidelines_review_
committee/en/). As the quotation above indicates, the presence of 
uncertainty in public health decision-making due to the nature of 
the available empirical evidence is one of the drivers for developing 
for these guidelines. To that end, their developers are tasked with 
assessing the strength of available evidence, including uncertainty 
due to analytic issues such as study design and statistical variability, 
using methodologies such as GRADE and evidence from systematic 
reviews (Figure A1), including performing such work themselves. 
Second, WHO produces policy guidance for a large number of 
Member States, and therefore the organization must determine 
the generalizability of research findings to diverse settings and/
or describe where and why uncertainties regarding translatability 
will need to be addressed. Third, while “WHO’s legitimacy and 
technical authority lie in its rigorous adherence to the systematic 
use of evidence as the basis for all policies,” as alluded to above, the 
outlined policy development practices embody an understanding 
that empirical evidence cannot serve as the sole consideration 
in decision making (Closing the Gap 2008, pp 42: www.who.int/
social_determinants/final_report/en/) and in policies that concern 
health equity and human rights. For example, end-user values and 
moral imperatives must also be considered (Closing the Gap 2008). 
Finally, WHO makes guidelines across a wide range of policy areas 
with a variety of associated evidence bases. Consequently, WHO 
policy recommendations and guidelines provide ideal cases to 
study how empirical tools to account for uncertainty operate in 
public health policy-making, which elements of scientific evidence 
assessments are successfully translated, which are absent, and 
whether elements of uncertainty from the policy-making process 
are either unaddressed by the available evidence or perhaps created 
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a new, based on the evidence. 
Description of Standard WHO Guideline Development Process
We reviewed the WHO Handbook for Guideline Development 
(http://apps.who.int/iris/handle/10665/145714)  to extract the key 
features of the WHO guideline development processes, specifically 
focusing on those we think are most relevant to the synthesis and 
translation of uncertainty from empirical evidence. We identified 
four critical features of the WHO guideline development process: 
the expressed commitment to principles, the constitution of special 
groups, the collection of evidence, and the evaluation of evidence. 
A descriptive summary of these features and the values that 
underpin them follows.
The first important feature is WHO’s stated commitment to a 
principle-based process. WHO defines guideline statements 
as “recommendations for clinical practice or public health 
policy,” allowing users to choose and prioritize “among different 
interventions or measures having an anticipated positive impact on 
health and implications for the use of resources” (WHO Handbook 
2014, pp 1). In accordance to their commitment to use the best 
science (see Setting and Rationale above), WHO observes the 
following principles, amongst others: “process and methods” that 
“aim to minimize the risk of bias in the recommendations”; develop 
recommendations “based on a systematic and comprehensive 
assessment of a policy’s or intervention’s potential benefits and 
harms”; and “recommendations can be implemented in, and 
adapted to, local settings and contexts” (pp 2). 
The constitution of groups with defined roles is the second 
notable feature. WHO convenes four groups to execute guideline 
development: the steering group administers the entire process 
including setting objectives, selecting expert groups, drafting 
recommendations, and overseeing dissemination; the guideline 
development group (GDG) consists of a multidisciplinary group 
of external (unpaid) experts assembled to assist in question 
development, assess and interpret GRADE or other evidence, 
and formulate recommendations; the external review group of 
varied stakeholders are brought in at various stages of policy 
development to complement missing perspectives from the GDG, 
and to specifically provided critiques of missing information and 
implications for implementation; and the systematic review team are 
contracted expert groups, for example members of the Cochrane or 
Campbell Collaborations, tasked to perform or update a systematic 
review of relevant evidence intended to form the basis of policy 
development. Further, it should be noted that both the GDG and 
external review groups are constituted to be composed of not only 
subject-matter experts, but also end users, representatives for 
target populations, “experts in assessing evidence and developing 
guidelines,” and economists or experts in equity, human rights, and 
gender as needed (WHO Handbook 2014, pp 25-26). 
How the evidence is collected comprises the third feature of 
WHO’s guideline development process. The initial stage of 
evidence collection following formal process initiation involves the 
formulation of questions that require empirical evidence to address. 
WHO further divides this process into background questions, 
whose answers provide context, and foreground questions, 
whose answers directly inform policy recommendations (WHO 
Handbook, pp 77). Background questions include mechanisms, 
prevalence, and distributional questions. Importantly, WHO 
recognizes that answers for these questions “may be found in a wide 
range of informational sources, ranging from basic scientific or 
pharmacokinetic data from animal studies, to surveillance data on 
incidence cases, to theoretical frameworks” (pp 78). Nonetheless, 
evidence to answer these questions “must be based on relevant and 
object evidence in order to generate a high level of confidence in 
the results” (pp 78). For example, data on incidence or prevalence 
“should be duly cited and justified” (pp 78). In contrast, foreground 
or key questions directly pertaining to intervention or policy 
recommendations including efficacy, effectiveness, potential 
harms, feasibility, and acceptability “are the most important ones 
for guideline development” (pp 79). Consequently, they “usually 
require a systematic review and assessment of the quality of the 
evidence” (pp 79). Moreover, WHO recommends formulation of 
such questions in PICO (Population, Intervention, Comparator 
Interventions, Outcomes) format, to capture the critical attributes 
of a considered policy.
To answer key questions in PICO format, WHO requires systematic 
review, which it defines as “a review of a clearly formulated 
question that uses systematic and explicit methods to identify, 
select, and critically appraise relevant research, and to extract and 
analyze data from the studies that are included in the review” (pp 
93). To produce these systematic reviews, WHO relies on literature 
and database searches as well as an existing relationship with the 
Cochrane Collaboration, a world-renown leader in systematic 
reviews. Citing several characteristics (Table A1), WHO envisions 
a proper systematic review to “reduce the risk of bias and improve 
the reliability an accuracy of conclusions based on evidence” (pp 
93). 
The last important feature relates to the evaluation of evidence. 
Upon collection of the evidence for systematic review, evaluations 
of the quality of evidence are conducted, either by in-house WHO 
Figure A1. Recommended Steps for Developing a Systematic 
Review (adapted from WHO handbook for guideline 
development, 2014).37
Figure A2. Quality of Evidence as Defined by the GRADE Framework 
(adapted from WHO handbook on guideline development, 2014).37
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staff, commissioned systematic reviewers, and/or the GDG under 
the guidance of the steering group, with an acknowledgement that 
an expert in evidence evaluation must be included. WHO provide 
general guidance for quality assessment, particularly on the use of 
the GRADE approach to assess the “extent to which one can be 
confident that an estimate of the effect of association is correct” 
or alternatively, “certainty of the evidence” or “confidence in the 
estimates of effect” (pp 110). Notably, GRADE is used to rate a body 
of evidence for a particular outcome, and not individual studies, 
based on a quality rating of High, Moderate, Low, and Very Low 
(Figure A2). By default, a body of evidence based on RCTs “is rated 
as being of high quality at the outset” while those based on other 
studies “as being of low quality” (pp 113). These ratings are then 
modified based on assessment of five criteria: “limitations in study 
design and execution; indirectness; imprecision; inconsistency; 
and publication bias” (pp 113). 
Importantly for our purposes, the principles of inconsistency, 
for example widely varying effect estimates, and imprecision, 
regarding wide confidence intervals, apply specifically to the 
concept of uncertainty due to statistical variability. Numerous tips 
are provided to reviewers on how to judge uncertainty due to wide 
confidence intervals in evidence. Interestingly, the role of GDGs in 
applying GRADE to assessing evidence is contrasted from standard 
systematic reviews, in that GDGs “need to consider the context 
when making a recommendation” rather than solely on the existing 
evidence itself (pp 117). Moreover, some general guidance is 
provided on how to evaluate the applicability of findings to different 
contexts, otherwise known as generalizability or “indirectness” 
(the lack of generalizability being indirectness). These include the 
closeness of the evidence to the PICO characteristics (ie, Is it the 
same population?) and the lack of evidence specifically comparing 
desired policy options. Finally, guidance is given on major criteria 
used to translate evidence into recommendations, including the 
quality of evidence previously adjudicated, values of users, benefits 
and harms, and resource implications (pp 123). Taken together 
with the use of opinions of a variety of stakeholders, it would seem 
that WHO has established a framework for evaluating the nature of 
uncertainty in the translation of evidence, particularly with regards 
to statistic variability and generalizability.
Table A1. WHO Characteristics of a Systematic Review, from page 93 of WHO Handbook on Guideline Development, 2014
•	 Specific, objective and clearly focused key questions;
•	 Explicit, transparent and reproducible methods;
•	 Pre-defined eligibility criteria for included studies;
•	 A comprehensive and systematic search for all studies that meet eligibility criteria;
•	 An assessment of the risk of bias of the included studies;
•	 A description and synthesis of the characteristics and findings of the individual studies and of the body of evidence; and
•	 Valid and clearly presented conclusions, with information on their applicability to the key question.
